CT-G11
- Generic Name
- CT-G11
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
Phase 1
Terminated
- Conditions
- Cardiomyopathy, Hypertrophic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 23
- Registration Number
- NCT04418297
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇵🇱Institute of Cardiology in Warsaw, Warsaw, Mazowieckie, Poland
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 72
- Registration Number
- NCT03918967
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath